Salarius Financial Statements From 2010 to 2025
| SLRX Stock | USD 0.91 0.06 6.19% |
Check Salarius Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Salarius Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Salarius financial statements analysis is a perfect complement when working with Salarius Pharmaceuticals Valuation or Volatility modules.
Salarius |
Salarius Pharmaceuticals Company Return On Equity Analysis
Salarius Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Salarius Pharmaceuticals Return On Equity | -1.11 |
Most of Salarius Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Salarius Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Salarius Pharmaceuticals has a Return On Equity of -1.1087. This is 95.37% lower than that of the Biotechnology sector and 96.96% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Salarius Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Salarius Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Salarius Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Salarius Pharmaceuticals competition to find correlations between indicators driving Salarius Pharmaceuticals's intrinsic value. More Info.Salarius Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Salarius Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Salarius Pharmaceuticals Financial Statements
Salarius Pharmaceuticals investors use historical fundamental indicators, such as Salarius Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Salarius Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. Salarius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.